Cenexi turnaround delay
Cenexi is still a few quarters away from a complete turnaround; Q2 will be impacted by extended summer shutdown.
GLAND / Q1-FY25 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
U.S. pricing pressure and product mix
U.S. market remains crowded; low-margin GPO contract and milestone income volatility could pressure margins.
Biologics collaboration execution risk
Discussions for a strategic biologics collaboration are early-stage; may require significant investment with uncertain timeline.
Fosun stake sale overhang
Fosun sold a large stake in the quarter; management has no visibility on future share sales, which could impact sentiment.